ESTRO 2024 - Abstract Book

S2253

Clinical - Upper GI

ESTRO 2024

Conclusion:

Radiotherapy for cT4 LAEC was shown to be well tolerated. Multidisciplinary treatment could aim to further improve treatment outcome.

Keywords: esophageal cancer, T4, proton beam therapy

2497

Digital Poster

Survival and morbidity after radiotherapy for oesophageal cancer; a retrospective study

Hanna Rahbek Mortensen 1 , Lone Hoffmann 2,3 , Marianne Nordsmark 2 , Lise Bech Jellesmark Thorsen 2 , Ditte Sloth Møller 2,3 1 Aarhus University Hospital, Danish Center for Particle Therapy, Aarhus, Denmark. 2 Aarhus University Hospital, Department of Oncology, Aarhus, Denmark. 3 Aarhus University, Department of Clinical Medicine, Aarhus, Denmark

Purpose/Objective:

Patients with esophageal and gastroesophageal junction (GEJ) cancer are offered (chemo-)radiotherapy if diagnosed with locally advanced disease. Standard treatment is neo-adjuvant chemo-radiotherapy followed by surgery for patients deemed resectable and operable, while treatment with definitive chemo-radiotherapy is suitable for patients with locally advanced disease who are not candidates for surgery. The aim of this study was to examine survival and morbidity in patients treated with radiotherapy for oesophageal cancer with curative intent.

Material/Methods:

This retrospective study included patients treated with radiotherapy with curative intent for oesophageal cancer at a single institution between January 2012 and March 2021. The primary endpoint was overall survival and secondary endpoints were loco-regional control, progression-free survival, pattern of failure, and toxicity. Data on patient characteristics were obtained from the Danish Oesophago-Gastric database, patient records, and data on dosimetric parameters from the dose planning system Eclipse. Treatment planning was based on a PET-CT scan in treatment position and target delineation was performed according to local and national guidelines. The gross tumor volume (GTV) was defined in cooperation with a radiologist and a nuclear medicine specialist and clinical target volume (CTV) was defined as a 3 cm cranio-caudal and 1 cm radial margin to the tumor GTV and a 1 cm margin to pathological lymph nodes. Since 2014 treatment was based on the mid-ventilation phase of a 4 dimensional CT scan. All patients were treated with IMRT and daily CBCT for setup. The prescribed dose to the CTV ranged from 41.4 Gy to 66 Gy in 23-33 fractions, 5 fractions per week.